Humira (adalimumab) is a biologic medication approved to treat nine different inflammatory conditions in adults and children. It works by blocking a protein called tumor necrosis factor (TNF), which drives inflammation throughout the body. Because chronic inflammation is the root of so many diseases, Humira became one of the most widely prescribed specialty drugs in the world, touching conditions from arthritis to skin disease to eye inflammation.
How Humira Works
Your immune system produces TNF as part of its normal defense against infection. In autoimmune and inflammatory diseases, the body overproduces TNF, which triggers pain, swelling, tissue damage, and other symptoms. Humira is an antibody that binds to TNF and neutralizes it before it can activate inflammatory pathways. This doesn’t cure the underlying disease, but it can dramatically reduce symptoms and, in some conditions, slow or stop permanent damage to joints, skin, and organs.
Rheumatoid Arthritis
Rheumatoid arthritis was Humira’s first approved use and remains one of its most common. It’s prescribed for adults with moderately to severely active disease to reduce joint pain, swelling, and stiffness, slow joint damage, and improve physical function. In clinical trials, about 64% of patients on the standard dose achieved at least a 20% improvement in symptoms by 24 weeks, compared to roughly 15% on placebo. More than a third of patients hit a 50% improvement threshold. Many people notice some relief within two weeks, though the full benefit can take 12 weeks or longer to develop.
Psoriatic Arthritis and Ankylosing Spondylitis
Humira treats two other forms of inflammatory arthritis. Psoriatic arthritis combines joint inflammation with the skin plaques of psoriasis, and Humira addresses both the joint and skin components. Ankylosing spondylitis primarily affects the spine and sacroiliac joints, causing stiffness and pain that’s typically worst in the morning. For both conditions, symptoms can begin improving within two weeks, though it may take 12 weeks or more. In addition to relieving pain and stiffness, Humira can slow the structural joint damage that leads to permanent disability in psoriatic arthritis.
Crohn’s Disease and Ulcerative Colitis
Humira is approved for moderately to severely active Crohn’s disease in adults and children aged six and older, and for moderately to severely active ulcerative colitis in adults. Both are inflammatory bowel diseases where the immune system attacks the digestive tract, causing abdominal pain, diarrhea, bleeding, and fatigue.
In ulcerative colitis, clinical remission rates in real-world studies reached about 17% at 4 weeks, climbing to 28% at 12 weeks and 43% by one year. That gradual improvement is typical. Some adults start seeing results within 4 weeks, but most notice meaningful change by 8 weeks. For Crohn’s disease specifically, Humira is effective both for patients who have never tried a biologic and for those who lost response to or couldn’t tolerate an earlier TNF blocker.
Plaque Psoriasis
For adults with moderate to severe plaque psoriasis, Humira can produce significant skin clearance. In two pivotal trials, 71% to 80% of patients achieved at least 75% clearer skin by 16 weeks, compared to 7% to 19% on placebo. Nearly half of patients reached 90% clearance. Humira is generally reserved for people whose psoriasis is widespread enough to warrant systemic treatment and for whom other systemic options aren’t a good fit. Most patients see meaningful improvement within about four months.
Hidradenitis Suppurativa
Hidradenitis suppurativa causes painful, recurring lumps and abscesses under the skin, typically in areas where skin rubs together like the armpits, groin, and under the breasts. It’s one of the more difficult dermatologic conditions to treat, and Humira was the first biologic approved for it. In clinical studies, Humira reduced the total number of inflammatory nodules and abscesses by at least 50% within 12 weeks. Notably, this is the one condition where the maintenance dose is weekly rather than every other week for most adults.
Uveitis
Humira treats non-infectious uveitis, an inflammatory condition affecting the middle and back portions of the eye. Left untreated, uveitis can lead to vision loss. Patients in clinical studies saw improvement in disease symptoms as quickly as six weeks. This indication covers adults with intermediate, posterior, or panuveitis, meaning the inflammation involves deeper structures of the eye rather than just the front surface.
Juvenile Idiopathic Arthritis
Children aged two and older with polyarticular juvenile idiopathic arthritis, a form of childhood arthritis affecting multiple joints, can be treated with Humira. Dosing is weight-based: children under 33 pounds receive 10 mg every other week, those between 33 and 66 pounds get 20 mg, and children 66 pounds and above receive the standard 40 mg adult dose.
How It’s Taken
Humira is a self-administered injection given under the skin, typically in the thigh or abdomen. It comes in pre-filled pens and syringes. For most conditions, the maintenance schedule is one injection every other week. The exceptions are hidradenitis suppurativa in adults (weekly injections) and conditions like Crohn’s disease and plaque psoriasis that start with higher loading doses before stepping down.
The medication needs to be stored in a refrigerator between 36°F and 46°F. If you’re traveling or otherwise away from a fridge, it can stay at room temperature (up to 77°F) for a maximum of 14 days. After that window, unused pens or syringes must be discarded.
Safety Risks to Know About
Because Humira suppresses part of the immune system, it carries serious risks that the FDA highlights with its strongest warning label. The primary concern is an increased risk of serious infections, including tuberculosis, invasive fungal infections, and bacterial infections from organisms like Legionella and Listeria. Before starting treatment, you’ll be tested for latent tuberculosis, and your doctor will monitor you for signs of infection throughout therapy. The risk is higher when Humira is combined with other immune-suppressing medications like methotrexate or corticosteroids.
The second boxed warning concerns malignancy. Cases of lymphoma and other cancers, some fatal, have been reported in children and young adults treated with TNF blockers. A rare but aggressive type called hepatosplenic T-cell lymphoma has occurred primarily in adolescent and young adult males with inflammatory bowel disease who were also taking certain other immunosuppressive drugs. Whether this risk comes from the TNF blocker itself or the combination of medications isn’t fully established.
Biosimilars and Alternatives
Humira’s patent exclusivity has ended, and there are now ten FDA-approved biosimilars available in the United States. Biosimilars are near-identical copies of the original biologic that work the same way and meet the same safety and efficacy standards. Seven of these biosimilars have been designated as interchangeable with Humira, meaning a pharmacist can substitute them without requiring a new prescription from your doctor. The availability of biosimilars has introduced lower-cost options for patients on adalimumab therapy, though insurance coverage and pricing vary.